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Friend of GATA proteins interact with GATA factors to regulate development in a variety of tissues. We analyzed cis- and trans-regulation of
the Drosophila gene, u-shaped, to better understand the transcriptional control of this important gene family during hematopoiesis. Using
overlapping genomic fragments driving tissue-specific reporter-gene (lacZ) expression, we identified two minimal hematopoietic enhancers within
the 7.4 kb region upstream of the transcription start site. One enhancer was active in all classes of hemocytes, whereas the other was active in
hemocyte precursors and plasmatocytes only. The GATA factor, Serpent, directly regulated the activity of both enhancers. However, activity in the
crystal cell lineage not only required Serpent but also the RUNX homologue, Lozenge. This is the first demonstration of GATA and RUNX direct
regulation of Friend of GATA gene expression and provides additional evidence for the combinatorial control of crystal cell lineage commitment
by Serpent, Lozenge, and U-shaped. In addition, we analyzed cis-regulation of ush expression in the lymph gland and identified similarities and
differences between regulatory strategies used during embryonic and lymph gland hematopoiesis. The results of these studies provide information
to analyze further the regulation of this conserved gene family and its role during hematopoietic lineage commitment.
© 2006 Elsevier Inc. All rights reserved.Keywords: Drosophila; Friend of GATA; GATA; Gene regulation; Hematopoiesis; RUNXIntroduction
Hematopoiesis is a tightly controlled process by which
specialized blood cells develop from a single pluripotent stem
cell. Central to this process is the orchestration of lineage-
specific developmental programs from diverse genetic networks
(Zhu and Emerson, 2002). These networks control the temporal
and spatial expression of key regulatory factors, some of which
form transient protein complexes that direct lineage differenti-
ation (Orkin, 2000). Current models depict lineage commitment
as a process that involves cross-antagonism between blood cell
programs, which promotes one lineage at the expense of the⁎ Corresponding author. Center for Vascular and Inflammatory Diseases and
the Department of Pathology, University of Maryland School of Medicine, 800
W. Baltimore Street, Room 215, Baltimore, MD 21201, USA. Fax: +1 410 706
8121.
E-mail address: nfossett@som.umaryland.edu (N. Fossett).
0012-1606/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2006.04.455others (Orkin, 2000). As a result, identifying key transcriptional
factors and understanding their precise regulation will serve to
explain how multiple genetic networks converge to specify cell
fate choice. Because of the remarkable conservation of gene
function, Drosophila genetics provides a facile approach to this
complex biological problem. Using this system, we previously
showed that combinatorial interactions between conserved
transcriptional regulators control lineage commitment (Fossett
et al., 2003). In this study, we more fully assessed the molecular
genetic mechanisms that direct these multifactor interactions.
The fly has a rudimentary blood system compared to that of
vertebrates. However, there are striking similarities between
vertebrate and Drosophila hematopoiesis. The two primary
Drosophila blood cell types, plasmatocytes and crystal cells,
have similar functions to cells of the vertebrate myeloid lineage
(Rizki, 1978; Dearolf, 1998; Evans et al., 2003). Crystal cells,
named for their crystalline inclusion bodies, are necessary for
wound healing and encapsulation of foreign invaders (Rizki,
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similar to monocytes, differentiate into macrophage-like cells
that phagocytize microbes and apoptotic cells (Rizki, 1978;
Tepass et al., 1994; Dearolf, 1998). Like their vertebrate
counterparts, the Drosophila blood cells develop from a
common hematopoietic progenitor (Rizki, 1978; Dearolf,
1998; Lebestky et al., 2000; Lanot et al., 2001). Furthermore,
an increasing number of conserved factors have been shown to
regulate blood cell development (Fossett and Schulz, 2001;
Evans et al., 2003 and references therein).
The GATA, Friend of GATA (FOG), and RUNX protein
families are of particular interest because these conserved
hematopoietic regulators act combinatorially to regulate lineage
commitment (Tsang et al., 1997, 1998; Elagib et al., 2003;
Fossett et al., 2003). The GATA family of transcription factors is
named for the consensus DNA sequence (WGATAR) to which
its members bind (Orkin, 1996; Parmacek and Leiden, 1999).
GATA factors generally have two zinc-finger domains. The
carboxyl (C)-terminal zinc-finger binds to the GATA recogni-
tion sequence, whereas the amino (N)-terminal zinc-finger both
stabilizes DNA binding and interacts with FOG proteins (Orkin,
1996; Trainor et al., 1996; Tsang et al., 1997). The FOG
proteins are multitype zinc-finger proteins with up to nine zinc-
fingers (Cubadda et al., 1997; Tsang et al., 1997; Tevosian et al.,
1999; Svensson et al., 1999; Lu et al., 1999). These factors
modify the activity of GATA transcription factors, enhancing or
antagonizing GATA activity depending on the gene regulatory
context (Tsang et al., 1997; Lu et al., 1999; Svensson et al.,
1999; Tevosian et al., 1999). The importance of the GATA:FOG
complex has been established using animal models and from
studies of heritable diseases resulting from GATA mutations
that block FOG binding (Haenlin et al., 1997; Tsang et al., 1998;
Deconinck et al., 2000; Fossett et al., 2000; Nichols et al., 2000;
Svensson et al., 2000; Tevosian et al., 2000; Yu et al., 2002;
Fossett et al., 2003). The GATA and FOG factors that have a
role in Drosophila hematopoiesis are Serpent (Srp) and U-
shaped (Ush), respectively (Rehorn et al., 1996; Sam et al.,
1996; Fossett et al., 2001; Waltzer et al., 2002; Fossett et al.,
2003). The srp gene is alternatively spliced to produce either a
single C-terminal zinc-finger isoform (SrpC) or the canonical
dual zinc-finger protein (SrpNC). Only SrpNC interacts with
Ush (Waltzer et al., 2002; Fossett et al., 2003). RUNX class
proteins are named for the pair rule gene, runt. These
transcriptional regulators bind to DNA through the conserved
Runt domain, and heterodimerization with Core Binding Factor
β has been shown to increase its binding affinity (Okuda et al.,
1996; Tracey and Speck, 2000; Adya et al., 2000; Rennert et al.,
2003). In general, Runx activity is influenced by a variety of
interacting transcriptional regulators, including GATA factors
(Coffman, 2003; Elagib et al., 2003; Fossett et al., 2003;
Waltzer et al., 2003). Of the three mammalian RUNX genes,
RUNX1 is required for hematopoiesis and is one of the most
frequent targets of chromosomal translocations associated with
human leukemia (Okuda et al., 1996; Speck and Gilliland,
2002; de Bruijn and Speck, 2004). Drosophila RUNX proteins
include the founding member, Runt; the hematopoietic factor,
Lozenge (Lz); and RunxA and RunxB (Rennert et al., 2003).Positioned at the apex of Drosophila hematopoiesis, Srp is
required for production of hemocyte precursors, which give
rise to the hematopoietic lineages (Rehorn et al., 1996; Sam et
al., 1996). Srp acts upstream of Lz and Glial cells missing
(Gcm), which are required for the production of crystal cells
and plasmatocytes, respectively (Bernardoni et al., 1997;
Lebestky et al., 2000; Kammerer and Giangrande, 2001;
Alfonso and Jones, 2002). In vertebrates, GATA-2, acting
analogously to Srp, is required for the production and survival
of pluripotent progenitors (Tsai and Orkin, 1997; Ling et al.,
2004). As hematopoiesis progresses, GATA-1 can interact with
either RUNX1 or FOG-1 to promote differentiation of the
erythroid biopotential precursor (Tsang et al., 1997, 1998;
Elagib et al., 2003). GATA-1 also interacts with FOG-1 to
block eosinophil production (Querfurth et al., 2000). Our
previous work in Drosophila shows that the functions of the
GATA/RUNX and GATA/FOG protein complexes are not only
conserved but that cross-talk between these complexes
precisely regulates crystal cell production (Fossett et al.,
2003). Specifically, SrpNC acts as a cross-regulatory switch,
interacting with Lz to upregulate the crystal cell program or
with Ush to block crystal cell production. Consequently, the
factors that regulate ush gene expression also affect this
contextual switch.
In addition to the functional similarity between the
Drosophila and vertebrate FOG proteins, both FOG genes
are expressed in a variety of hematopoietic cells during
developmental stages ranging from pluripotency to terminal
differentiation (Tsang et al., 1997; Fossett et al., 2001; Cantor
and Orkin, 2005). FOG genes are also downregulated in some
lineages to permit differentiation (Querfurth et al., 2000;
Fossett et al., 2001). FOG-1 is expressed at low levels in
hematopoietic stem cells and at high levels in early
hematopoietic progenitors, erythrocytes, and megakaryocytes.
FOG-1 is downregulated in eosinophils (Tsang et al., 1997;
Cantor and Orkin, 2005). In Drosophila, ush is highly
expressed in hemocyte precursors and throughout the
development of the plasmatocyte lineage. ush is also expressed
in crystal cell precursors but downregulated as these cells
develop (Fossett et al., 2001). Thus, the precise regulation of
FOG genes is evident by their intricate developmental and
lineage-specific expression patterns. Moreover, as discussed
above, the exacting regulation of FOG gene expression
undoubtedly contributes to the precise formation of transient
multiprotein complexes, which can redirect lineage develop-
mental pathways. Finally, the potential to place the FOG genes
in the context of known developmental pathways will certainly
add to our understanding of FOG function. For these reasons,
we initiated an analysis of the cis- and trans-regulation of
Drosophila ush expression during hematopoiesis. We have
defined the ush embryonic cis-regulatory region, showing that
most of the cis-elements reside within the region 7.4 kb
upstream of the transcription start site. Using this information,
we identified two minimal embryonic hematopoietic enhancers
and characterized the regulation of ush expression during
hematopoiesis. One enhancer is active in all classes of
hemocytes, whereas the other is active in hemocyte precursors
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we showed that Srp directly regulates ush enhancer activity in
all hemocytes. However, our data indicate that Srp alone is not
sufficient to upregulate ush hematopoietic expression. Srp
must also act with Lz to upregulate ush enhancer activity in
crystal cell precursors. These findings represent the first
demonstration of GATA and RUNX regulation of FOG gene
expression. We also analyzed cis-regulation of ush expression
in the lymph gland. This identified similarities and differences
between regulatory strategies used by hemocytes during
embryonic and lymph gland hematopoiesis. Our studies have
generated information that will be used to further analyze these
important transcriptional regulators.
Materials and methods
Fly strains
Fly stocksweremaintained at 23°Con standard food, andw1118was used as the
wild-type stock. The following fly lines were used in this study and are described
elsewhere: upstream activation sequence (UAS)-ush, UAS-srpNC and twiGal4
(Fossett et al., 2001, 2003). UAS-srpC was a generous gift of Deborah K.
Hoshizaki (University of Nevada, Los Vegas, NV). Dmef2Gal4 was a generous
gift fromElizabethChen (JohnsHopkins, Baltimore,MD) ru1 h1 th1 st1 cu1 srp3 sr1
es ca1/TM3, Sb1 Ser1 (srp3) was obtained from the Bloomington Stock Center. The
generation of strains carrying ush enhancer-lacZ transgenes is described below.Table 1
List of oligonucleotide primers
Primer name Forward
Wild-type fragments
−12475/−6925 gatacatacatttggagtgaaagagagatag
−7462/−25 ggcccgctccctttgtctgcactcag
−2190/−25 ctctcagaggactgttttttt
−1421/−25 gttcaggtgaaattacactgtgttctg
1809/7908 ttagggtattcgcttcaaactacca
6640/12678 atctactccgacctacccaactcac
−1421/−25 gttcaggtgaaattacactgtgttctg
−1421/−956 gttcaggtgaaattacactgtgttctg
−1421/−1215 gttcaggtgaaattacactgtgttctg
−1243/−956 tgcaagagagttagcgg
−1014/−352 tacagagagcaaaatgagagagagcgg
−420/−25 gatacagagatacaattaaacacaaaacg
−420/−172 gatacagagatacaattaaacacaaaacg
−237/−25 tcagtgcttcagtgtttgtgtatc
−174/−25 ttctgtttctgcgatgttatct
−174/−85 ttctgtttctgcgatgttatct
Mutant fragments
−1243/−956 3xGATAm method: PCR directed
distGATA1 gtcaacaatggcaaacgagcgcatcgtcgcaaaggcagccagcag
distGATA2,3 gtttttcgtggcgctaccccaatatatat
−1243/−956 3xGATAm tgcaagagagttagcgg
−237/−25 3xGATAm method: Stratagene SDM
proxGATA1 tttctgtttctgcgatgtgcgctaagcgcagagctcgc
proxGATA2,3 gcgctgcgctcctgcgcagtgcttgcgcag
−174/−85 m competitor method: PCR, template −237/−25 3xGATAm
proxGATGm ttctgtttctgccttgtgcgct
−174/−25 Runxm method: PCR
proxRunxm ttctgtttctgcgatgttatct
SrpC cDNA
XhoSrp/SrpXba aaaactcgagtcatacgcctacccagctctacgag
Mutated sequences are in bold and underlined.Generation of transgenic animals carrying ush enhancer-lacZ fusion
constructs
The overlapping DNA fragments used to identify the ush cis-regulatory
enhancers were generated by PCR amplification using BAC clone BACR48E08
(obtained from the BACPAC Resource Center at Children's Hospital, Oakland
Research Institute). The sequences of oligonucleotide primers used to generate
the fragments are listed in Table 1. All PCR reactions were performed with
TaKaRa LA Taq™ Polymerase (TaKaRa). These fragments were cloned into the
pCRII-TOPO cloning vector (Invitrogen) and subsequently subcloned into the P
element CaSpeR-Hsp43-AUG-βgal (Chab) germline transformation vector
(Thummel et al., 1988).
Three different methods were used to introduce site-directed mutations
(SDM) into DNA fragments. First, SDM was performed using the Stratagene
QuikChange II XL Site-Directed Mutagenesis Kit, according to the manufac-
turer's instructions (Stratagene). Second, PCR-mediated SDMwas performed as
described by Barettino et al. (1994), except that all of the targets were cloned
into the pCRII-TOPO cloning vector (Invitrogen). Finally, standard PCR
reactions were performed using oligonucleotide primers with mutated
transcription factor binding sites. The oligonucleotide primers used to generate
SDM in DNA fragments are as listed in Table 1.
The sequence of each recombinant vector was verified prior to injection.
yw67c23 or w1118 embryos were injected with these recombinant vectors by
Model Systems Genomics of Duke University or at The University of Texas, M.
D. Anderson Cancer Center. Germline transformants were established according
to previously described methods and were screened for tissue-specific lacZ
expression using immunohistochemical analysis as previously described
(Gajewski et al., 1997). At least five independent lines were generated and
tested for each construct.Reverse Use
gccacaacaaggacacacaacagagcaatag Enhancer
tcggctaagaggtctcgtctcgtcc Enhancer
tcggctaagaggtctcgtctcgtcc Enhancer
tcggctaagaggtctcgtctcgtcc Enhancer
cataaatgtcgcttccttcgattac Enhancer
cgtcatcgatattgttattgtt Enhancer
tcggctaagaggtctcgtctcgtcc Enhancer
ttctttcccagcgataacaatctccttc Enhancer
cgtgccgcttgccgctaactctcttgc Enhancer
ttctttcccagcgataacaatctccttc Enhancer/EMSA
ctacggctaatggaattctgattattg Enhancer
tcggctaagaggtctcgtctcgtcc Enhancer
aacagaaacagaaccaaaaccaac Enhancer
tcggctaagaggtctcgtctcgtcc Enhancer
tcggctaagaggtctcgtctcgtcc Enhancer
cggaattattcgaaacaaaaactga Enhancer/EMSA
Enhancer/EMSA
ctgctggctgcctttgcgacgatgcgctcgtttgccattgttgac
ttctttcccagcgcgcacaatctccttc
ttctttcccagcgcgcacaatctccttc
Enhancer
gcgagctctgcgcttagcgcacatcgcagaaacagaaa
ctgcgcaagcactgcgcaggagcgcagcgc
EMSA
tcggctaagaggtctcgtctcgtcc
Enhancer/EMSA
ggacgagccgagacctcttagccgagactctctgcaaagggcgacttcc
cDNA cloning
tttgtctagagatagattttagatagatgagtgttctttg
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and larvae
Collection, fixation, and immunohistochemical staining of embryos were
performed as previously described (Gajewski et al., 1999; Schulz and Fossett,
2005). The following primary antibodies were used: rabbit anti-Ush, 1:500
(Fossett et al., 2001); rabbit anti-Odd-skipped, 1:500 (a generous gift from
James Skeath, Washington University School of Medicine, St. Louis, MO);
rabbit anti-Serpent, 1:1000 (a generous gift of Mark Brennan, University of
Louisville, Louisville, KY); mouse anti-β-galactosidase, 1:500 (Promega).
Secondary antibodies were either biotinylated or conjugated with fluorescent
dyes and are as follows: biotinylated horse anti-mouse, 1:1000 (Vector
Laboratories); biotinylated goat anti-rabbit, 1:1000 (Vector Laboratories);
Alexa Fluor 555 donkey anti-mouse, 1:300 (Invitrogen); Alexa Fluor 488
chicken anti-rabbit, 1:300 (Invitrogen). Biotinylated secondary antibodies were
detected using the ABC-Elite-peroxidase kit (Vector Laboratories) with
diaminobenzidine as a substrate. Embryos were mounted in 50% glycerol and
visualized using Zeiss Axioplan optics. Embryos stained with secondary
antibodies conjugated with fluorescent dyes were mounted in ProLong Gold
anti-fade reagent (Invitrogen) and visualized using Zeiss confocal microscopy.
The confocal images were analyzed by Volocity software (Improvision).
Larval lymph glands were dissected and fixed as previously described
(Cripps et al., 1998). To assess β-galactosidase activity, the lymph glands were
histochemically stained with mouse anti-β-galactosidase, 1:2000 in PBS
containing 0.1% Triton X-100 (PBT) for 1 h at room temperature. After
incubation, the lymph glands were washed 10 times for 1 min each in PBT.
Subsequently, they were incubated in biotinylated secondary horse anti-mouse
IgG, 1:2000 for 1 h at room temperature. They were again washed 10 times for
1 min each in PBT and then processed for chromogenic detection as described
above for embryos. Stained preparations were mounted in 50% glycerol under
cover slips and visualized using Zeiss Axioplan optics.
Gene expression analysis in mutant and Gal4/UAS embryos
Embryos were cultured and collected at 23°C. ush enhancer-lacZ activity
was assayed in srp3 homozygous embryos after a two generation cross. Males
carrying ush enhancer-lacZ constructs on chromosome II were crossed to ru1 h1
th1 st1 cu1 srp3 sr1 es ca1/TM3, Sb1 Ser1 virgin females. F1 enhancer-lacZ/+; srp
3/
+ trans-heterozygous progeny were intercrossed. The F2 progeny from this cross
were collected during embryogenesis and assayed for β-galactosidase activity
using immunohistochemistry. Because ush enhancer-lacZ activity is readily
detectable as a single copy, 75% of the entire F2 population will have lacZ
expression if Srp is not required for enhancer activity. In contrast, if Srp is
required for enhancer activity, 75% of the wild-type embryos will show lacZ
expression, whereas none of the srp mutant embryos will exhibit lacZ
expression in the hematopoietic or midgut tissues. srp3 is a null allele due to a
point mutation in the C-terminal zinc-finger, which blocks DNA binding
(Rehorn et al., 1996). Because Srp is required for germ band retraction,
homozygous mutants are easily identified by the altered morphology that results
from failure of the germ band to retract.
Enhancer activity assessment in Srp gain of function backgrounds also
required a two generation cross. Each enhancer line was crossed to twiGal4
virgin females to produce twiGal4/+; ush enhancer/+ trans-heterozygous
progeny. The F1 virgin females were collected and then crossed to either
UAS-srpNC or UAS-srpC homozygous males. The F2 progeny from this cross
were collected during embryogenesis and immunohistochemically stained with
the β-galactosidase antibody as previously described (Gajewski et al., 1997).
Homozygous twiGal4 virgins were crossed to homozygous UAS-ush males to
produce twiGal4/+; UAS-ush/+ embryos. Lymph gland development in these
embryos was assayed by analyzing the expression of Serpent and Odd-skipped
using immunohistochemical staining.
Gel shift assays
Full-length srpC and srpNC cDNAs were cloned into the pCMV-TNT®
vector (Promega) using the following strategy. The srpC coding region was PCR
amplified using DNA isolated from UAS-srpC fly strains (Hayes et al., 2001)
and the XhoSrpC and SrpCXba primers (Table 1). The resulting fragment wascloned into the pCR II-TOPO vector. srpNC was cloned as previously described
(Fossett et al., 2003). Each srp clone was isolated from its respective pCR-II
TOPO vector using KpnI/XbaI restriction endonuclease digestion. The
restriction fragments were isolated and subcloned into the pCMV-TNT® vector,
and the sequence of each clone was verified. The lz cDNA was cloned into
pET3C (kindly provided by Richard W. Carthew, Northwestern University,
Evanston, IL). Using these cDNA clones, SrpC, SrpNC or Lz proteins were
produced by TNT® coupled in vitro transcription/translation (Promega)
according to the manufacturer's instructions. DNA probes corresponding to
wild-type or mutant versions of the ush hematopoietic enhancers were prepared
by PCR amplification of the respective pCRII-TOPO clones. Oligonucleotide
primers used to generate the probes are listed in Table 1. The PCR products were
purified by gel extraction (Qiagen). The purified fragments were then end-
labeled with 32P in a reaction using T4 polynucleotide kinase (Roche). The gel
shift assay binding reactions were performed using 4 μl of the appropriate TNT
product and respective end-labeled DNA probe. For competition binding assays,
increasing amounts of excess unlabeled wild-type and mutated DNAwere used.
Competitor DNAwas added 10 min prior to the end-labeled probe. All binding
reactions were incubated on ice for 20 min. The binding reactions were
separated on 0.5× TBE non-denaturing polyacrylamide gels at 4°C. Gels were
dried and were visualized using the Molecular Dynamics STORM analysis
system.Results
ush embryonic cis-regulatory elements reside within a 7.4 kb
region upstream of the transcription start site
The ush gene is expressed in a variety of tissues throughout
embryogenesis. These include the anterior and posterior
midgut, dorsal ectoderm, fat body, visceral and cardiogenic
mesoderm, and hematopoietic tissues, specifically the hemo-
cyte precursors, plasmatocytes and crystal cells (Fossett et al.,
2000, 2001). The precise temporal and spatial regulation of this
intricate expression pattern is undoubtedly controlled by a
broad array of transcriptional regulators. These trans-acting
factors bind to cis-elements that likely reside within a 32 kb
region, which has previously been shown to contain the ush
locus (Cubadda et al., 1997). This region contains a 15 kb
upstream noncoding sequence and a 17 kb transcribed
sequence that includes a 10.5 kb intron located between
exons 2 and 3 (Fig. 1A).
To begin identification of the cis-elements and trans-acting
factors that control ush expression, we conducted a screen for
genomic DNA fragments that drive tissue-specific reporter-
gene (lacZ) expression. As described in the Materials and
methods section, PCR amplification was used to generate
overlapping fragments from the upstream noncoding region,
between positions −12475 and −25, and from the downstream
transcribed region, between positions 1809 and 12678, which
includes intron 2 (Fig. 1A). Using this approach, we identified a
7.4 kb enhancer, located between positions −7462 and −25,
which recapitulates endogenous ush expression. The develop-
mental staging of embryos showed that Ush and β-galactosi-
dase were first detected in the amnioserosa during stage 7 (Fig.
1B panels a, b). By stage 8, both proteins were observed in the
hemocyte precursors (Fig. 1B panels f, g). During stage 10, Ush
and β-galactosidase were observed in the developing hemo-
cytes, midgut, and dorsal ectoderm (Fig. 1B panels k, l, m, and
data not shown). In these tissues, expression continued until the
Fig. 1. Delineation of the ush cis-regulatory region. (A) Schematic of the ush locus and the screen for cis-regulatory elements. The locus is complemented by a 30 kb
ush+ cosmid, which rescues the embryonic lethal phenotype. A horizontal arrow indicates the transcription start site, designated position 0 with respect to the ush locus.
From left to right, the three black boxes represent exons 1, 2, and 3–8. The nearby lesswright gene is depicted in grey. A dotted line indicates the upstream region. The
DNA fragments used to screen for enhancers are indicated by black lines and are positioned and numbered relative to the transcription start site. Solid lines represent
enhancers with activity; the dashed line represents a fragment lacking activity. The asterisks designate representative enhancer data presented in part B. (B)
Comparison of endogenous Ush and enhancer-driver reporter-gene (lacZ) expression patterns during embryogenesis. The stage of embryogenesis is indicated at the
left of each row. Stages 7, 8, and 10 (panels a-o) are viewed laterally, and stages 13 and 16 (panels p–y) are dorsal views. The wild-type (panels a, f, k, p, u) and ush
enhancer (panels b–e, g–j, l–o, q–t, v–y) strains are indicated at the top of each column. The antibodies used for immunohistochemical localization are listed at the
bottom of each column. Solid arrows indicate activity in representative tissues; open arrows indicate lack of activity in crystal cells. Abbreviations: lwr, lesswright;
αUsh, U-shaped antibody; αβ-gal, β-galactosidase antibody; wt, wild type; as, amnioserosa; hp, hemocyte precursors; mg, midgut; de, dorsal ectoderm; cc, crystal
cells.
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Beginning about stage 11 and continuing through stage 13, Ush
and β-galactosidase were detected in the bilateral cluster of
developing crystal cells (Fig. 1B panels p, q, and data not
shown). Later, during stage 16, both proteins were observed in
the circulating plasmatocytes (Fig. 1B panels u, v). Despite the
overall similarity, some differences were observed between the
expression patterns of the endogenous protein and the enhancer-
driven reporter-gene. First, ush expression is downregulated
during crystal cell maturation (Fossett et al., 2001; Fig. 1B panelu). In contrast, enhancer activity in these cells persisted until the
late stages of embryogenesis (Fig. 1B panel v). This difference
may be due to the long half-life of the β-galactosidase protein.
Second, ush is expressed in cells of the developing central
nervous system (Fossett et al., 2000). However, none of the
fragments tested had activity in these cells (data not shown).
Thus, elements that drive this activity may be located outside
the region tested. Alternatively, expression may require the
combined activity of elements in two or more of the DNA
fragments.
566 S. Muratoglu et al. / Developmental Biology 296 (2006) 561–579The region upstream of position −7462 and the region within
intron 2 were less active in embryonic tissues when compared to
the 7.4 kb enhancer. A fragment located between positions
−12425 and −6925 lacked activity until stage 10, when weak
activity was detected in the dorsal ectoderm (Fig. 1B compare
panels d, i, n). By stage 13, we observed strong activity in the
dorsal ectoderm and amnioserosa (Fig. 1B panel s). This
activity appeared to be identical to that seen with the 7.4 kb
enhancer (Fig. 1B compare panels q and s), suggesting it is
regulated by elements within the 537 bp overlap between the
−12475/−6925 bp fragment and the −7462/−25 bp enhancer.
By stage 16, we observed strong activity in the dorsal ectoderm
and posterior midgut that did not resemble either endogenous
ush or 7.4 kb enhancer-driven reporter-gene expression (Fig. 1B
compare panels u and v with x). This atypical activity may be
due to the absence of repressor elements within the −12475/
−6925 bp fragment. We also assayed intron 2 for enhancer
activity by dividing this region into two overlapping fragments
(Fig. 1A). The first fragment contained the 5′ half of intron 2,
from position 1809 to 7908, and lacked activity until
approximately stage 13 (Fig. 1B panels e, j, o). At this time,
enhancer activity was observed in the anterior amnioserosa (Fig.
1B panel t). By stage 16, activity in the dorsal mesoderm was
observed (Fig. 1B panel y). The second fragment contained the
3′ half of intron 2, from position 6640 to 12678, and had no
activity (data not shown). Thus, of the four large fragments that
covered most of the noncoding region, only the −7462/−25 bp
fragment largely recapitulated the expression pattern of ush and
was the only fragment with enhancer activity in the hemato-
poietic tissues.
Identification of ush embryonic hematopoietic enhancers
In the Drosophila embryo, Srp-expressing hemocyte pre-
cursors develop from the head mesoderm (Rehorn et al., 1996;
Sam et al., 1996). Identified by specific markers that include the
extracellular matrix component, peroxidasin, the emerging
plasmatocyte population begins to migrate throughout the
head mesoderm during stage 10. By mid-embryogenesis, these
cells can be seen circulating throughout the endolymph (Tepass
et al., 1994; Fig. 1B panels f, k, p, u). In contrast, the smaller
crystal cell population, distinguished by the cell-specific
expression of lz and members of the melanin cascade, initially
develops as bilateral clusters in the head mesoderm (Lebestky et
al., 2000; Fig. 1B panels p–r). After stage 13, the clusters begin
to merge forming a single population that resides anterior to the
developing gut (Lebestky et al., 2000).
Using this positional information together with genetic and
immunocolocalization studies, we previously reported that ush
is expressed in embryonic hemocyte precursors, plasmatocytes,
and crystal cell precursors; subsequently, it is downregulated
during crystal cell development. This broad expression pattern
suggests that Ush, like FOG-1, has a variety of functions
throughout hematopoiesis. In addition, like its vertebrate
counterpart, the function of Ush depends on its association
with other transcriptional regulators, notably the GATA factors
and C-terminal Binding Protein (CtBP; Fossett et al., 2000,2001, 2003). These associations produce dynamic multiprotein
complexes that can alter cell fate choice (Fossett et al., 2003).
The assembly of these regulatory complexes will be affected by
the level of ush expression and, therefore, by those factors that
control its expression. Thus, a greater knowledge of ush gene
regulation will increase our understanding of its function. For
this reason, we produced subfragments of the 7.4 kb enhancer
to precisely define the ush hematopoietic cis-regulatory region.
Two overlapping subfragments with hematopoietic activity
were designated the −2190/−25 bp enhancer and the −1421/
−25 bp enhancer (Fig. 1A). Using the hemocyte positional
information described above, we compared the hematopoietic
activity of the −2190/−25 bp enhancer (Fig. 1B panels c, h, m,
r, w) and the −1421/−25 bp enhancer (Fig. 2B panels a, e, i, m,
q) with the activity of the 7.4 kb enhancer (Fig. 1B panels b, g,
l, q, v). All three produced indistinguishable temporal and
spatial expression patterns, suggesting that the essential
elements directing embryonic hematopoietic activity are
located within the −1421/−25 bp enhancer.
We further subdivided the −1421/−25 bp hematopoietic
enhancer into nine overlapping fragments. The analysis of
these fragments identified two minimal hematopoietic enhan-
cers. These enhancers are located within the 5′ distal (−1243/
−956 bp) region and 3′ proximal (−174/−25 bp) region of the
−1421/−25 bp enhancer, and are separated by a region of
approximately 800 bp that lacks hematopoietic activity (Fig.
2A). The distal enhancer had activity in the hemocyte
precursors and plasmatocytes but lacked crystal cell activity
(Fig. 2B panels b, f, j, n, r). The proximal enhancer retained
much of the activity of the parental −1421/−25 bp enhancer,
with activity in the hemocyte precursors, plasmatocytes, and
most notably crystal cells (Fig. 2B panels c, g, k, o, s). Thus,
elements that are required for ush expression in the hemocyte
precursors and plasmatocytes are located within the proximal
and distal enhancers, whereas crystal cell-specific elements are
restricted to the proximal enhancer (Fig. 2A). To more
precisely locate the crystal cell-specific elements, we deleted
60 bp from the 3′ region of the proximal enhancer to produce
an 89 bp truncated proximal enhancer located between
positions −174 and −85 (Fig. 2A). This enhancer retained
hemocyte precursor and plasmatocyte activity but lacked
crystal cell activity (Fig. 2B, panels d, h, l, p, t). Thus, the
crystal cell-specific elements are located between positions −85
and −25.
In addition to the embryonic hemocytes, the −1421/−25 bp
enhancer was active in the midgut (Fig. 2B panels e, i, m). We
analyzed the nine overlapping subfragments to determine the
location of the midgut enhancer. This analysis showed that the
distal −1421/−956 bp hematopoietic enhancer lacked midgut
activity (data not shown). The distal −1243/−956 bp minimal
hematopoietic enhancer also lacked midgut activity in the
majority of embryos tested (Fig. 2B panels f, j, n). However, in
three of the six lines tested, 30% of the embryo population
retained midgut activity. This is in contrast to the parental
−1421/−956 bp enhancer, which completely lacked midgut
activity. At this time, we cannot exclude the possibility that the
reduced midgut activity of the −1243/−956 bp enhancer is the
Fig. 2. Identification of minimal ush embryonic hematopoietic enhancers. (A) Schematic of the screen for minimal hematopoietic enhancers. The DNA fragments used
to locate the minimal hematopoietic enhancers are indicated by black lines and are positioned and numbered relative to the transcription start site. Solid lines represent
enhancers with activity; the dashed lines represent fragments lacking activity. The asterisks designate representative enhancer data presented in part B. Blue lines
indicate the minimal region required for ush expression in hemocyte precursors and plasmatocytes. The red line indicates the minimal region required for ush
expression in all classes of hemocytes. (B) Comparative embryonic enhancer activity. The stage of embryogenesis is indicated at the left of each row. Lateral views of
stage 9 and 10 embryos (panels a–h), dorsal views of stage 13 and 16 embryos (panels i–p) and dorsal views of the head region of stage 13 embryos (panels q–t) are
presented. The ush enhancer strains are indicated at the top of each column. Solid arrows indicate activity in representative tissues; open arrows indicate lack of activity
in crystal cells. Abbreviations: hp, hemocyte precursors; mg, midgut; cc, crystal cells; pl, plasmatocytes.
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In contrast to the results obtained with the distal hematopoietic
enhancers, the proximal −420/−25 bp enhancer was consistent-
ly active in the midgut, similar to the parental −1421/−25 bp
enhancer (data not shown). However, the −237/−25 bp and the
−174/−25 bp subfragments had greatly diminished midgut
activity (Fig. 2B panels d, k, o, and data not shown). Finally, the
−420/−172 bp fragment and the −174/−85 bp truncated
proximal hematopoietic enhancer did not have activity (Fig.
2B panels h, l, p, and data not shown). Thus, full midgutenhancer activity required multiple elements located between
positions −420 and −25.
Srp directly regulates ush hematopoietic expression
We analyzed the sequences within the minimal enhancers to
identify trans-acting factors that regulate ush hematopoietic
expression during embryogenesis. A number of observations
suggested that Srp might directly regulate ush expression.
First, Srp is required for endogenous ush expression (Fossett et
568 S. Muratoglu et al. / Developmental Biology 296 (2006) 561–579al., 2001). Second, twenty-two GATA binding sites are located
within the −1421/−25 bp enhancer. Six of these (three each)
are located in the proximal and distal minimal enhancers.
Finally, two of the three sites within the distal enhancer and all
three sites within the proximal enhancer are conserved
between Drosophila melanogaster and D. pseudoobscura
(Fig. 3A).
In order to determine if Srp directly regulates ush expression,
we first tested enhancer activity in embryos with altered Srp
function. The activities of the 7.4 kb enhancer, −1421/−25 bp
enhancer, and active subfragments were assayed in embryos
with Srp loss of function or gain of function genetic
backgrounds. As described in the Materials and methods
section, we performed a two generation cross to assay enhancer
activity in a Srp loss of function background. In these studies,
we used the srp3 allele, which has a point mutation in the C-
terminal zinc-finger that prevents DNA binding and results in
complete loss of activity. Srp is required for a variety of
developmental processes, including germ band retractionFig. 3. Srp is required for ush enhancer activity in hematopoietic tissues. (A)
embryonic hematopoietic enhancers. The region between −7.4 kb and −1.4 kb
enhancers. GATA sites labeled with blue arrowheads are conserved between D.
enhancer data presented in part B. (B) ush enhancer activity in embryos with
genetic backgrounds are indicated at the left of each row and are as follows: wild
(panels i–l); twiGal4-driven UAS-srpNC (panels m–p). The ush enhancer strains
representative tissues; arrowhead indicates expanded midgut activity and open ar
pl, plasmatocytes; mg, midgut.(Rehorn et al., 1996). Thus, homozygous mutants are easily
identified by the altered morphology resulting from this
phenotype (Fig. 3B compare panels a–d with e–h). In a
homozygous srp3 mutant background, none of the enhancers
showed hematopoietic activity (Fig. 3B panels e–h, and data not
shown). We obtained the same results using the hypomorphic
srpneo45 allele (data not shown). Therefore, Srp function is
required for enhancer activity.
Gain of function studies were conducted using the UAS/Gal4
binary system developed by Brand and Perrimon (1993).
twiGal4 was used to drive Srp expression throughout the
mesoderm, including the hematopoietic mesoderm. In twiGal4-
driven UAS-srpC or UAS-srpNC embryos, the activity of the
7.4 kb enhancer was dramatically increased, and expression
could be seen throughout the mesoderm and mesectoderm (Fig.
3B panels i, m, and data not shown). Endogenous Ush has a
similar expression pattern to the 7.4 kb enhancer in Srp gain of
function embryos (Fossett et al., 2003). In contrast, the proximal
−174/−25 bp enhancer showed a minimal increase in activity,Schematic showing the relative positions of the 7.4 kb (−7462/−25) and
is condensed. Red vertical lines indicate GATA sites within the minimal
melanogaster and D. pseudoobscura. The asterisks designate representative
altered Srp function. Lateral views of stage 13 embryos are presented. The
type (panels a–d); homozygous srp3 (panels e–h); twiGal4-driven UAS-srpC
are indicated at the top of each column. Closed arrows indicate activity in
rows indicate lack of activity. Abbreviations: wt, wild type; cc, crystal cells;
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−174/−85 bp truncated proximal enhancer showed increased
activity in Srp gain of function embryos (Fig. 3B panels j, k, l, n,
o, p). The difference between the 7.4 kb enhancer and the
minimal hematopoietic enhancers may be at least partially due
to cis-regulatory elements within the 7.4 kb enhancer that drive
midgut activity. This interpretation is supported by our data
showing that forced-expression of Srp slightly expanded the
diminished midgut activity observed with the proximal −174/
−25 bp enhancer (Fig. 3B panels k, o) and greatly expanded the
activity of enhancers that produced full midgut activity, such as
the −420/−25 bp enhancer (data not shown). The failure of Srp
to expand the expression domain of the minimal hematopoietic
enhancers suggested either that it does not directly regulate ush
hematopoietic expression, or it acts with additional factors to
drive expression in hematopoietic tissues. To distinguish
between these possibilities, we determined whether Srp directly
regulates the distal and proximal minimal hematopoietic
enhancers. Direct activation would involve Srp binding to the
GATA recognition sites within the minimal enhancers.
Furthermore, these sites would be required for enhancer activity
in vivo.
Using gel shift studies, we showed that both SrpC and
SrpNC bind to radiolabeled DNA fragments corresponding to
the distal −1243/−956 bp enhancer and −174/−85 bp truncated
proximal enhancer (Figs. 4A, B lanes 1, 2, 7, and data not
shown). Next, to determine if Srp would specifically bind to the
GATA sequences within each fragment, we performed compe-
tition-binding assays using both wild-type and mutated
fragments (Fig. 4A). Excess unlabeled wild-type fragment
effectively competed for Srp binding (Fig. 4B lanes 1–5, 7–10,
and data not shown). Mutation of all GATA sites within each
fragment produced partial competition for binding, suggesting
that both Srp isoforms bind to other sequences within the
minimal enhancers (data not shown). Because vertebrate GATA
factors have been shown to bind GATG, GATT, and GATC
sequences with varying affinities (Pedone et al., 1997; Newton
et al., 2001), we surveyed the region from position −174 to −85
for GAT core sequences. We located a GATG site between
positions −161 and −158 and mutated this site along with the
three GATA sites (Fig. 4A). This fragment failed to compete for
Srp binding (Fig. 4B lanes 6, 11), indicating that both Srp
isoforms bind to GATG sites. This result is consistent with
studies that showed the N-terminal zinc-finger of vertebrate
GATA factors bind to this site (Pedone et al., 1997).
To determine if the GATA sites are required for enhancer
activity in vivo, we mutated these sites and then tested the
resulting enhancers for hematopoietic activity. When all three
GATA sites in the distal enhancer were mutated, complete
loss of enhancer activity was observed (Figs. 4A, C compare
panels a, e, i with b, f, j). The proximal −237/−25 bp
enhancer has four conserved GATA sites and one GATG site.
Mutating all three GATA sites between positions −174 and
−85, but not the 5′ GATA or GATG site, also resulted in
complete loss of enhancer activity (Figs. 4A, C compare
panels c, g, k, with d, h, l). Thus, although both Srp isoforms
bind to the GATA and GATG sites, this interaction isinsufficient for enhancer activity. Together, these data indicate
that while Srp directly regulates ush expression, it is not
sufficient for ush hematopoietic enhancer activity. Thus,
additional factors may act with Srp to upregulate ush
expression in hematopoietic tissues.
Srp and Lz are required for ush expression in crystal cells
Consistent with its function as a repressor of crystal cell
production, Ush is expressed in the crystal cell lineage and
downregulated as these cells develop (Fossett et al., 2001). As
we have shown in this report, ush enhancer activity in the
crystal cell lineage appears to be driven by element(s) located
between positions −85 and −25. We surveyed this region and
identified a consensus RUNX sequence located between
positions −66 and −60 (Fig. 5A). In addition, several other
observations suggested that Lz mediates ush expression in the
crystal cell lineage. First, Ush and Lz are coexpressed in
hemocyte and crystal cell precursors (Lebestky et al., 2000;
Fossett et al., 2001), providing the opportunity for Lz to regulate
ush expression. Second, the RUNX site is present in the
proximal enhancer but not the distal enhancer, consistent with
the lack of crystal cell activity displayed by this enhancer.
Finally, like many of the GATA sites, the RUNX site is
conserved between D. melanogaster and D. pseudoobscura
(Fig. 5A). Based on this information, we tested if Lz directs ush
enhancer activity in the crystal cell lineage.
The direct activation of ush expression by Lz would be
mediated through binding to the RUNX site. An in vitro
transcribed/translated protein and a radiolabeled fragment
corresponding to the proximal −174/−25 bp enhancer were
used in gel shift studies to show that Lz binds to the enhancer
(Fig. 5A). To establish the specificity of this interaction, we
showed that excess unlabeled wild-type fragment effectively
competed for Lz binding (Fig. 5B lanes 1–4). In contrast, a
fragment containing a mutated RUNX site was a poor
competitor (Fig. 5B lane 5). This mutated fragment was also
tested for enhancer activity in vivo and was found to be active in
hemocyte precursors and plasmatocytes but not crystal cells
(Figs. 5A, C compare panels a, c with b, d). Together, results
from these in vitro and in vivo studies indicate that Lz directly
activates ush expression in the crystal cell lineage.
The data presented in this report indicate that Srp is required
for ush expression in all hematopoietic tissues, including the
crystal cells (Fig. 3). And, more to the point, Srp may upregulate
expression in crystal cells by binding to conserved GATA sites
that are located within the proximal −174/−25 bp enhancer (Fig.
4). Furthermore, ush expression in crystal cells also appears to
require Lz binding to a conserved site, which is located 3′ and in
close proximity to the cluster of conserved GATA sites (Fig. 5).
Together, these findings suggest that Srp and Lz interact to
positively regulate ush expression in the crystal cell lineage.
Regulation of ush expression during both hematopoietic waves
In both vertebrates and Drosophila, hematopoiesis consists
of two spatially and temporally separated periods or waves. In
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hematopoiesis and takes place in the extraembryonic yolk sac.
The second or definitive wave originates in the aorta/gonad/
mesonephros region of the embryo proper (Cumano and Godin,
2001). To this point, we have examined ush expression during
the first wave of Drosophila hematopoiesis. The first wave
begins with the formation of the hematopoietic anlage from the
head mesoderm. As embryogenesis progresses, hemocyte
precursor cells develop in this region and later give rise to theplasmatocytes and crystal cells (Rizki, 1978; Dearolf, 1998). In
keeping with the mammalian system, we will refer to the first
hematopoietic wave as embryonic hematopoiesis. The second
wave takes place in a specialized organ known as the lymph
gland. For this reason, the second wave will be referred to as
lymph gland hematopoiesis. The lymph gland develops from
the cardiogenic mesoderm beginning about embryonic stage 13.
By the end of embryogenesis, it has formed two bilateral lobes
that flank the developing heart (Rugendorff et al., 1994; Mandal
571S. Muratoglu et al. / Developmental Biology 296 (2006) 561–579et al., 2004). Morphological and gene expression analyses show
that the lymph gland becomes highly compartmentalized by the
end of the third larval instar (Jung et al., 2005) and functions
until the onset of metamorphosis (Holz et al., 2003; Evans et al.,
2003).
We previously showed that ush is expressed in the third
larval instar lymph gland (Fossett et al., 2001). Using
fluorescent antibody staining and confocal microscopy, we
observed weak ush expression in the stage 16 embryonic lymph
gland (Fig. 6A panel a). This is contrasted with the strong
expression seen in both the cardiogenic mesoderm precursor
cells (Fossett et al., 2000; L. Mandal, personal communication)
and third larval instar lymph gland descendents (Fossett et al.,
2001; Fig. 6A panel b). We judged the relative strength of Ush
expression by visually comparing the level of staining across
tissues within the same developmental time point. Using this
method, we observed that the third larval instar lymph gland and
the cardiogenic mesoderm had staining that was greater than or
equal to the majority of Ush-expressing tissues within these
time points (Fossett et al., 2000, 2001; Fig. 6A panel b). In
contrast, expression in stage 16 embryonic lymph glands was
considerably less than that observed in the neighboring cells of
the amnioserosa (Fig. 6A panel a), as well as other Ush-
expressing tissues. Together these data suggest that ush
expression is downregulated during lymph gland specification
but rebounds as the lymph gland develops. To test if
downregulation of ush expression is necessary to permit
lymph gland development, we expressed ush pan-mesodermally
using the twiGal4 driver and assayed for embryonic lymph
gland development using the Odd-skipped (Odd) and Srp
markers. Lymph gland development in either twiGal4 or
Dmef2Gal4-driven UAS-ush embryos was greatly impaired
compared to wild-type controls (Fig. 6B and data not shown).
Interestingly, twiGal4-driven UAS-ush embryos survive, hatch,
and progress through the life cycle to adulthood (data not
shown). Because twi expression is downregulated during the
later stages of embryogenesis, ectopic Ush expression may
similarly wane. This may allow for the recovery of the
developing lymph gland during the early larval stages.
However, impairment of lymph gland development should not
affect the number of circulating hemocytes in non-immune
challenged larvae because this population consists of embryonic
hemocytes that persist throughout the life cycle (Holz et al.,
2003). These embryonic hemocytes may compensate for theFig. 4. Srp directs ush enhancer activity through GATA recognition sites. (A) Schem
GATA directed activity in vivo. Red vertical lines show the relative positions of 7 GA
−174/−85 bp truncated proximal enhancer. The grey vertical line indicates the GATG
and D. pseudoobscura. Red and grey lines that have been crossed out with the letter X
and grey lines on each enhancer represent the orientation of the GAT core sites, with s
Competition gel shift assay showing Srp isoforms bind to the −174/−85 bp truncated
enhancer (lane 1) was shifted by the addition of either SrpC or SrpNC (lanes 2 and 7,
20-, 100-, and 200-fold excess of unlabeled wild-type competitor (lanes 3, 4, 5, and 8,
GATA/GATG mutant version of the truncated proximal enhancer (lanes 6 and 11). Ar
type and GATA mutant enhancer activity. The stage of embryogenesis is indicated at
(panels e–l) are dorsal views. Enhancer strains are indicated at the top of each colum
lack of activity. Abbreviations: 3xGATAm, three GATA sites mutated; m competit
transcribed/translated Srp protein; hp, hemocyte precursors; pl, plasmatocytes; cc, closs of lymph gland derived hemocytes, which may help to
explain the survival of twiGal4-driven UAS-ush animals.
In addition to ush, a number of regulatory factors function
during both hematopoietic waves, including Lz and Srp
(Lebestky et al., 2000; Evans et al., 2003; Jung et al., 2005).
However, recent studies have highlighted differences between
embryonic and lymph gland hematopoiesis. The lymph gland is
organized into morphologically distinct zones, characterized by
the degree of hemocyte maturation and the expression of
various markers (Jung et al., 2005). Moreover, the zinc-finger
protein Odd is expressed during the second wave of
hematopoiesis but not the first (Ward and Skeath, 2000; Jung
et al., 2005). In contrast, Gcm may not be expressed during
lymph gland hematopoiesis but is required for embryonic
plasmatocyte development (Bernardoni et al., 1997; Bataille et
al., 2005). Given these differences, we evaluated cis-regulation
of ush expression in the developing embryonic lymph gland and
the third instar larval lymph gland. We then compared cis-
regulation of ush expression during both hematopoietic waves.
Enhancer activity in the embryonic lymph gland was
determined by evaluating the colocalization of Odd and β-
galactosidase. Odd is expressed throughout the lobes of the
developing lymph gland, the pericardial cells, and a number of
other tissues during embryogenesis (Ward and Skeath, 2000;
Mandal et al., 2004). Third instar larval lymph glands were
removed and then tested for enhancer-driven β-galactosidase
expression using immunohistochemistry. A subset of the
hematopoietic enhancers had strong activity in both the
embryonic and third instar larval lymph glands (Fig. 7A). As
expected, the 7.4 kb enhancer was active in both the embryonic
and third instar larval lymph glands (Figs. 7A, B panels a, g).
The −2190/−25 bp enhancer was also active in both the
embryonic and third instar larval lymph glands (Figs. 7A, B
panels b, h). In contrast, the −1421/−25 bp enhancer had
reduced activity in lymph glands during both developmental
stages (Figs. 7A, B panels c, i). Similarly, the distal −1243/
−956 bp minimal hematopoietic enhancer and a larger version
of the distal enhancer (−1421/−956 bp) also had reduced lymph
gland activity (Figs. 7A, B panels d, j, and data not shown).
Considering the weak activity of the −1421/−25 bp enhancer,
the strong activity of the −420/−25 bp deletion product of this
enhancer was quite unexpected (Figs. 7A, B panels e, k). Thus,
by deleting the −2190 to −1422 region, we produced the −1421/
−25 bp fragment, which had severely reduced enhancer activity.atic showing the mutated fragments used to evaluate Srp binding in vitro and
TA sites within the distal −1243/−956 bp enhancer, −237/−25 bp enhancer, and
site. Blue arrowheads indicate GATA sites conserved between D. melanogaster
indicate GATA sites that were mutated in these studies. The positions of the red
ites running 5′ to 3′ above the line and those running 3′ to 5′ below the line. (B)
proximal enhancer. A 32P-labeled version of the −174/−85 bp truncated proximal
respectively). Srp binding to the labeled probe was abolished by the addition of
9, 10). The same competition reaction was repeated using 200-fold excess of the
rows point to the free probe and the Srp-DNA complex. (C) Comparison of wild-
the left of each row. Stage 10 embryos (panels a–d) are lateral views; all others
n. Closed arrows indicate activity in representative tissues; open arrows indicate
or, mutant competitor; wt competitor, wild-type competitor; Srp-TNT, in vitro
rystal cells.
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produced the −420/−25 bp fragment, which restored enhancer
activity (Fig. 7A). Together, these data indicate that the −2190/
−25 bp enhancer contains multiple domains, which regulate ush
expression in the lymph gland. Specifically, ush expression is
upregulated by the combinatorial activity of elements located in
the −2190/−1421 bp and −420/−25 bp regions, whileexpression is repressed by elements located in the −1421/
−420 bp region. Finally, in contrast to the parental −420/−25 bp
enhancer, the −237/−25 bp and −174/−25 bp deletion products
had weak activity during development of the embryonic lymph
gland but strong activity in the third instar larval lymph gland
(Figs. 7A, B panels f, l, and data not shown). These results
suggest that during early lymph gland development, full ush
Fig. 6. Ush expression and lymph gland development. (A) The Ush expression
pattern in stage 16 lymph glands. Anterio-dorsal view of fluorescent antibody
stained embryonic lymph gland (panel a). Arrows indicate weak staining in the
lymph gland and ring gland. Arrowhead indicates strong staining in the
amnioserosa. Immunohistochemical stained third larval instar lymph gland
(panel b). (B) Forced mesodermal expression of ush blocks lymph gland
development. Dorsal views showing embryonic stage 16 lymph gland
development in wild-type (panels a, c) and twiGal4-driven UAS-ush (panels
b, d) genetic backgrounds. Lymph glands are visualized with anti-Odd (panels a,
b) and anti-Srp (panels c, d) antibodies. Closed arrows indicate embryonic
lymph gland; open arrows indicate reduced lymph gland development.
Abbreviations: as, amnioserosa; elg, embryonic lymph gland; llg, larval
lymph gland; αUsh, U-shaped antibody; rg, ring gland; lg, lymph gland; a,
anterior lobe; p, posterior lobe; wt, wild type; twi>ush, twiGal4-driven UAS-
ush; αOdd, anti-Odd-skipped antibody; αSrp, anti-Serpent antibody.
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positions −420 and −237.
The ability of the −2190/−1421 bp region to relieve the
lymph gland-specific repressor activity of the −1421/−420 bp
fragment suggested that this region contained an additional
hematopoietic enhancer. Consistent with this hypothesis, we
observed clustered GATA and RUNX binding sites located
between positions −1619 and −1558, which are similar to those
of the proximal −174/−25 bp enhancer. To test this hypothesis,
we generated nine separate transgenic lines that carried the
−2190/−1421 bp fragment upstream of the lacZ reporter-gene
and assayed these for hematopoietic-specific reporter-gene
expression during embryonic and lymph gland hematopoiesis
(Figs. 7A, C).
Our analysis of the parental −2190/−25 bp enhancer showed
that in all of the transgenic lines 100% of the stage 8 to 10Fig. 5. The proximal −174/−25 bp enhancer contains a conserved RUNX site that bin
−174/−25 bp enhancer. The red vertical lines show the relative position of GATA site
arrowheads indicate the sites that are conserved betweenD. melanogaster andD. pseu
for hemocyte precursor and plasmatocyte activity. The red horizontal line indicates the
the wild-type (in black) and mutant (in red) RUNX site. (B) Competition gel shift
enhancer. A 32P-labeled version of the proximal −174/−25 bp enhancer (lane 1) was sh
addition of 50- and 100-fold excess unlabeled wild-type competitor (lanes 3 and 4). Th
version of the proximal enhancer (lane 5). Arrows point to the free probe and the Lz-D
The stage of embryogenesis is indicated at the left of each row. All embryos are do
carrying wild-type (panels a, c) and RUNX-mutant (panels b, d) proximal enhance
arrows indicate lack of activity in crystal cells. Abbreviations: RUNXm, RUNX-mut
TNT, in vitro transcribed/translated Lz protein; pl, plasmatocytes; cc, crystal cells.embryo population had enhancer-driven β-galactosidase activ-
ity in hemocyte precursors (Fig. 1B panels g, l). Similarly, 100%
of the stage 11 to 15 embryo population had activity in both the
plasmatocyte and crystal cell lineages (Fig. 1B panel g and data
not shown). The same results were obtained with the −1421/
−25 bp enhancer and with all three proximal enhancers (−420/
−25 bp, −237/−25 bp and −174/−25 bp enhancers; Fig. 2B
panels a, c, e, g, l, k, q, s and data not shown). In contrast, the
activity of the −2190/−1421 bp fragment differed significantly
from this pattern. As a result, we classified β-galactosidase
activity as aberrant when greater than 40% of the embryo
populationwithin a given developmental stage deviated from the
pattern observed with the parental −2190/−25 bp enhancer.
Using this criterion, we determined that eight of the nine −2190/
−1421 bp enhancer transgenic lines had activity in stage 8 to 10
hemocyte precursors (Fig. 7C panels a, b; Table 2). In contrast,
only two lines were active in both the crystal cell and
plasmatocyte lineages (Fig. 7C panel c; Table 2). We observed
that four lines had activity in only one of the blood cell lineages;
two lines had activity in crystal cells only and two lines had
activity in plasmatocytes only (Fig. 7C panels d, e; Table 2). Two
lines lacked activity in both lineages (Fig. 7C panel f; Table 2).
Finally, five of the eight lines had ectopic activity in the dorsal
ectoderm that was not evident in the parental −2190/−25 bp
enhancer (Table 2 and data not shown). Together these data
suggest that an additional embryonic hemocyte precursor
enhancer lies upstream of position −1421. However, sustained
expression in developing hemocytes requires the −1243/
−956 bp and −174/−25 bp enhancers. Furthermore, elements
within the −1421/−25 bp region are required to block non-
specific expression.
During lymph gland hematopoiesis, −2190/−1421 bp frag-
ment-driven β-galactosidase expression was not detected in the
embryonic lymph gland or in the anterior lobe of the third larval
instar lymph gland (Fig. 7C panels g–j and data not shown).
However, expression was detected in a subpopulation of cells in
the posterior lobe of the third larval instar lymph gland (Fig. 7C
panels g–j). Taken together, our analyses of the −2190/−25 bp
enhancer indicate that the −2190/−1421 bp region is necessary
but not sufficient for ush expression during early lymph gland
development and hemocyte maturation in the anterior lobe of
the third larval instar lymph gland. As such, we have designated
the −2190/−1421 bp fragment an activator region rather than an
enhancer (Fig. 7A). However, an additional hemocyte precursor
enhancer within the −2190/−1421 bp region, possibly the sameds Lz and is required for activity in crystal cells. (A) Schematic of the proximal
s, and the green vertical line shows the relative position of the RUNX site. Blue
doobscura. The blue horizontal line indicates the region of the enhancer required
region required for activity in all three hemocyte classes. The sequence is that of
assay showing that Lz binds to the conserved RUNX site within the proximal
ifted by the addition of Lz (lane 2). Lz binding to the probe was abolished by the
e competition reaction was repeated using 100-fold excess of the RUNX-mutant
NA complex. (C) Comparison of wild-type and RUNX-mutant enhancer activity.
rsal views. Enhancer strains are indicated at the top of each column. Embryos
rs are presented. Closed arrows indicate activity in representative tissues; open
ant; m competitor, mutant competitor; wt competitor, wild-type competitor; Lz-
Fig. 7. Identification of enhancers that regulate ush expression in the embryonic and larval lymph glands. (A) Schematic summarizing the lymph gland activity of the
hematopoietic enhancers. The region between −7.5 kb and −2.5 kb is condensed. The hematopoietic enhancers are positioned and numbered relative to the
transcription start site. Enhancers depicted with blue lines have strong activity in the developing embryonic and third instar larval lymph glands. Those depicted in red
have strong activity in the larval lymph gland but weak activity in embryonic lymph gland. Those in grey have weak lymph gland activity during both developmental
stages. The green line depicts the activator region. The letter “B” or “C” to the right of each line indicates data that are presented in part B or C, respectively. The
multicolored green, grey, and blue line depicts the regulatory domains within the −2190/−25 bp enhancer. (B) Embryonic and larval lymph gland activity of
representative hematopoietic enhancers. The hematopoietic enhancer strains are designated at the top of each column. The top panels (a–f) show the expression of Odd
(green) and enhancer-driven dβ-galactosidase (red) proteins in stage 16 embryonic lymph glands. Colocalization of these proteins is shown in yellow. All embryos are
anterior-dorsal views. Arrows indicate the lymph gland and pericardial cells. Arrowheads indicate areas with the greatest degree of colocalization between the β-
galactosidase and Odd proteins. Bottom panels (g–l) show enhancer-driven β-galactosidase expression in larval lymph glands. (C) Activity of the −2190/−1421 bp
region during both hematopoietic waves. The top panels (a–f) show −2190/−1421 bp fragment-driven β-galactosidase expression during embryogenesis. The stage of
embryogenesis is indicated in the lower right corner. Lateral views of stage 8 and 10 embryos (panels a, b) and dorsal views of stage 13 embryos (panels c–f) are
shown. Solid arrows indicate activity in hemocytes; open arrows indicate lack of activity in hemocytes. The bottom panels (g–j) show −2190/−1421 bp fragment
activity during third larval instar lymph gland hematopoiesis in four different transgenic lines. Abbreviations: lg, lymph gland; elg, embryonic lymph gland; llg, larval
lymph gland; Odd, Odd-skipped; β-gal, β-galactosidase; pc, pericardial cells; a, anterior lobe; p, posterior lobe; h, heart; emb, embryogenesis; hp, hemocyte
precursors; pl, plasmatocytes; cc, crystal cells.
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Table 2
−2190/−1421 bp fragment driven β-galactosidase activity
Transgenic
line
Percentage of embryo population with β-galactosidase activity
Stages
8–10
hp
Stages
11–15
pl, cc
lineages
Stages
11–15
neither
lineage
Stages
11–15
pl only
Stages
11–15
cc only
Stages
8–15
ectopic de
#25 0 a 0 a 100 a 0 0 100 a
#19 100 0 a 0 0 100 a 0
#37 100 0 a 0 0 100 a 0
#40 100 33 a 42 a 3 21 42 a
#62 100 43 a 13 43 a 0 50 a
#85 100 43 a 0 45 a 12 0
#57 100 56 a 6 32 6 6
#84 100 65 0 29 6 87 a
#46 100 96 0 4 0 100 a
This table shows the percentage of the embryo population with β-galactosidase
activity in hematopoietic tissues for all nine transgenic lines. This table also
shows the percentage of the embryo population with ectopic dorsal ectoderm
activity for each line. Abbreviations: hp, hemocyte precursors; pl, plasmato-
cytes; cc, crystal cells; de, dorsal ectoderm.
a Aberrant expression: greater than 40% of the population differs from the
parental −2190/−25 bp enhancer activity.
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hematopoiesis, may control β-galactosidase expression in the
posterior lobes of the mature lymph gland.
We found both similarities and differences in the regulation
of ush expression during the two hematopoietic waves. ush
expression appears to be controlled by a shared proximal
enhancer located between positions −174 and −25, which
upregulates expression during both embryonic and third instar
larval lymph gland hematopoiesis (Figs. 2A, 7A). We have also
identified three differences in the regulatory process. First, the
proximal −174/−25 bp minimal hematopoietic enhancer is
active throughout the embryonic wave (Fig. 2B panels c, g, k,
o). In contrast, during the second wave this minimal enhancer is
only fully operational in the mature lymph gland, as additional
upstream element(s) are required for full expression in the
developing lymph gland (Figs. 7A, B panels e, f, l, and data not
shown). Second, a distinct distal enhancer located between
positions −1243 and −956 upregulates ush expression during
embryonic but not lymph gland hematopoiesis (Figs. 2A, B
panels b, f, j, n, r; 7A, B panels d, j). Third, proximal enhancer
activity is repressed by the −1421/−420 bp region during lymph
gland but not embryonic hematopoiesis. Thus, both shared and
divergent regulatory programs are used during each hemato-
poietic wave.
Discussion
The Drosophila FOG gene, ush, is expressed in a variety of
embryonic tissues and during hematopoiesis (Fossett et al.,
2001). We surveyed the ush locus for DNA fragments that drive
tissue-specific reporter-gene expression. Results obtained from
this screen identified a 7.4 kb ush embryonic cis-regulatory
region that included a proximal and distal minimal hematopoi-
etic enhancer. These enhancers were then used to identify trans-
acting regulators of ush hematopoietic expression. We showedthat Srp upregulates enhancer activity in all hemocytes, whereas
Lz together with Srp is required to upregulate enhancer activity
during crystal cell lineage commitment (Fig. 8A). Our findings
represent the first demonstration of direct regulation of FOG
gene expression by GATA and RUNX factors. We also
identified similarities and differences in the cis-regulation of
ush during embryonic and lymph gland hematopoiesis (Fig.
8B). The information obtained from these studies will be used to
identify additional regulators of ush hematopoietic expression
and assign novel functions to those that are currently known.
Srp regulation of ush expression
Our results indicate that Srp directly activates ush hemato-
poietic expression through binding to the GATA recognition
sequences within the ush proximal and distal enhancers. The
direct activation of FOG gene expression by GATA factors may
be evolutionarily conserved. This hypothesis is also supported
by vertebrate tissue culture studies that showed endogenous
FOG-1 gene expression increased in response to exogenous
GATA-1 protein and from the observed overlap of vertebrate
GATA and FOG gene expression in a variety of developing
tissues (Tsang et al., 1997; Tevosian et al., 1999; Svensson et al.,
1999; Lu et al., 1999; Gaines et al., 2000; Cantor and Orkin,
2005). However, our studies show that Srp function alone may
not be sufficient to upregulate ush hematopoietic expression.
twiGal4-driven UAS-srp is expressed throughout the mesoderm
(Fossett et al., 2003). If Srp was the sole activator of the ush
hematopoietic enhancers, we would expect to see pan-
mesodermal enhancer activity. Instead, we observed a minimal
increase in the activity of the proximal −174/−25 bp enhancer
and no increase in the activity of the distal −1243/−956 bp
enhancer and the −174/−85 bp truncated proximal enhancer.
Moreover, these results complement our previous findings that
ush is expressed considerably later than srp during hemocyte
precursor development (Fossett et al., 2001). Taken together,
these results indicate that additional factors work with Srp to
upregulate ush expression during hematopoiesis (Fig. 8A). This
is consistent with studies showing that multiple classes of
transcription factors activate prototypical cis-regulators
(Howard and Davidson, 2004; Levine and Davidson, 2005).
Furthermore, the requirement for multiple activators of ush
prevents the unrestricted coexpression of Srp and Ush in
hemocytes. This additional regulatory feature, together with
alternative splicing, may limit the formation of the SrpNC:Ush
complex. Strict control of complex formation is critical
considering the impact this complex has on hemocyte
development and function. In this regard, the SrpNC:Ush
complex blocks expression of an important component of
programmed cell death, croquemort (Franc et al., 1999; Waltzer
et al., 2002), and, as discussed above, limits crystal cell
production (Fossett et al., 2003).
Srp and Lz regulation of ush expression in crystal cells
Our previous studies showed that SrpNC acts as a cross-
regulatory switch during crystal cell lineage commitment.
Fig. 8. cis- and trans-regulation of ush hematopoietic expression. (A) Model showing Srp regulation of ush hematopoietic expression. Srp and additional factors drive
ush expression in hemocyte precursors and plasmatocytes, whereas Srp and Lz activate ush expression in crystal cells. The downregulation of ush expression by
SrpNC and Lz promotes crystal cell maturation and proliferation. Solid lines indicate that direct regulation of enhancers by transcriptional regulators has been
demonstrated; dotted lines indicate that direct regulation has not been demonstrated. The model is a simplification of the regulation of ush expression and does not
necessarily include all of the factors required for proper temporal and spatial expression. (B) Schematic showing the relative positions of hematopoietic cis-regulatory
regions. A horizontal arrow indicates the transcription start site, designated position 0 with respect to the ush locus. From left to right, the three black boxes represent
exons 1, 2, and 3–8. The nearby lesswright gene is depicted in grey. A dotted line indicates the 7.4 kb upstream region. The 2.2 kb hematopoietic regulatory region is
shown below the ush locus in expanded form. The relative positions of enhancers (blue), repressors (red), and activators (green) are shown. These cis-regulatory
regions are also positioned vertically from top to bottom according to whether they are shared or are specific for embryonic or lymph gland hematopoiesis.
Abbreviations: hp, hemocyte precursors; pl, plasmatocytes; cc, crystal cells; lwr, lesswright; emb, embryonic hematopoiesis; lg, lymph gland hematopoiesis.
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Ush to block crystal cell production (Fossett et al., 2003). Thus,
the regulation of Ush expression will have a direct affect on the
cross-regulatory activity of SrpNC. Interestingly, our new
findings indicate that ush expression is maintained during
crystal cell lineage commitment by the combined actions of Srp
and Lz. It seems counterproductive for the crystal cell activator,
Lz, to be a positive regulator of the crystal cell repressor, Ush.
However, this negative regulatory strategy may be an important
control to limit crystal cell production. In this model, Srp and Lz
activate ush expression in Lz-positive hemocyte precursors
(Fig. 8A). Ush then binds to the alternatively spliced Srp
isoform, SrpNC, converting it from a crystal cell lineage
coactivator with Lz to a repressor (Fossett et al., 2003). As a
result, the Srp:Lz-directed crystal cell program is subject to
negative regulation. In support of this model, only 60% of Lz-
positive hemocyte precursors become terminally differentiated
crystal cells (Bataille et al., 2005). Furthermore, these data
suggest that Lz is not only required for crystal cell specification
and differentiation but also to limit crystal cell production by
positively regulating ush expression. Interestingly, Lz also acts
as both a transcriptional repressor and activator within a single
cell of the eye primordium (Canon and Banerjee, 2003).
Because the RUNX proteins have been shown to be both
positive and negative transcriptional regulators, this may be aconserved characteristic of the RUNX family. In general,
RUNX activity may be dependent on the specific coregulator
and the developmental context (Coffman, 2003).
Previously, we showed that Ush is downregulated by the
combined actions of Lz and SrpNC (Fossett et al., 2003). This
would limit the formation of the SrpNC:Ush repressor complex
making more SrpNC available to interact with Lz, thereby
positively regulating crystal cell lineage commitment. Together
with our previous findings, these new results indicate that the
Drosophila GATA, FOG, and RUNX factors are part of a
highly interactive cross-regulatory network that rigorously
controls crystal cell number. Finally, given that GATA-1, FOG-
1, and RUNX1 function during vertebrate megakaryopoiesis
(Tsang et al., 1998; Song et al., 1999; Gaines et al., 2000;
Nichols et al., 2000; Michaud et al., 2002; Walker et al., 2002;
Elagib et al., 2003), the cross-regulatory control of FOG gene
expression by GATA and RUNX factors may be conserved
across taxa.
Srp and Lz bind to GATA and RUNX sites that are contained
within a 97 bp region of the proximal −174/−25 bp enhancer.
The juxtaposition of these sites suggests that Srp and Lz
physically interact to upregulate ush expression. This is
consistent with a previous report that showed these proteins
form a complex in vitro (Waltzer et al., 2003). Thus, it is
possible that a Srp:Lz complex binds to the adjacent GATA and
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the adjacent sites, facilitating their subsequent interaction. In
either case, the proximity of the sites likely promotes the
cooperative, cell-specific upregulation of ush. Moreover, this
arrangement of elements may be present in other GATA:Runx
responsive genes that regulate Drosophila crystal cell and
vertebrate megakaryocyte development.
SrpNC and Lz could also mediate repression of ush by
binding to the GATA and RUNX sites. This interpretation is
supported by our previous studies that showed SrpNC and Lz
blocked ush expression but SrpC and Lz did not. These results
suggest that repression by SrpNC and Lz likely requires
additional corepressors (Fossett et al., 2003). However,
repression mediated through the proximal enhancer may also
require input from additional cis-elements. This would be
analogous to the repression of the proximal enhancers by the
−1421/−420 bp region that occurs during lymph gland
hematopoiesis. Alternatively, SrpNC and Lz may not directly
block expression but rather act upstream of direct regulators of
the ush gene (Fig. 8A).
cis-regulation of ush during both hematopoietic waves
We observed three basic differences in the cis-regulation of
ush during both hematopoietic waves, indicating that divergent
gene regulatory networks control aspects of embryonic and
lymph gland hematopoiesis. First, our results demonstrated that
although the proximal −174/−25 bp enhancer is completely
operational during both embryonic hematopoiesis and third
larval instar hematopoiesis, the region located between posi-
tions −420 bp and −25 bp is required for full ush expression in
the embryonic lymph gland (Fig. 8B). The −420/−25 bp
enhancer has eleven conserved GATA sequences as compared
to three within the proximal −174/−25 bp enhancer (data not
shown). In view of this difference, an increase in Srp binding
may be required for full enhancer activity in the embryonic
lymph gland. Srp has been shown to be expressed in the early
embryonic lymph gland (Mandal et al., 2004). Second, the 1 kb
region located between positions −1421 bp and −420 bp
represses proximal enhancer activity during lymph gland but
not embryonic hematopoiesis. While activity can be restored by
factors that bind to elements located between −2190 bp and
−1421 bp, this region is largely unable to drive expression in the
absence of the proximal enhancers (Fig. 8B). Thus, trans-
activators recruited by the −2190/−1421 bp region are able to
circumvent lymph gland-specific repression by acting syner-
gistically with the proximal enhancer machinery. Finally, other
than Srp, the distal −1243/−956 bp enhancer is activated by
factors largely specific for embryonic hematopoiesis and
different from those that regulate the proximal −174/−25 bp
enhancer. Alternatively, the −1243/−956 bp region may bind
lymph gland-specific repressors that downregulate its activity
during this hematopoietic wave.
These differences in ush regulation are not surprising
considering the divergent developmental strategies of the
embryonic and larval hematopoietic tissues and their respec-
tive ush expression patterns. During embryogenesis, hemocyteprecursors develop from the head mesoderm (Rizki, 1978;
Dearolf, 1998). srp expression is first detected in these cells
during embryonic stage 5 (Rehorn et al., 1996; Sam et al.,
1996). ush expression is first observed in the hemocyte
precursors during stage 8, increases during embryogenesis, and
remains constant in plasmatocytes throughout embryogenesis
(Fossett et al., 2000, 2001). In contrast, the lymph gland
hemocyte precursors develop from the cardiogenic mesoderm
beginning around embryonic stage 13 (Rugendorff et al.,
1994; Mandal et al., 2004). Furthermore, unlike embryonic
hematopoiesis, ush displays a bimodal expression pattern
during this second hematopoietic wave. ush is strongly
expressed in the cardiogenic mesoderm (Fossett et al., 2000)
but downregulated during lymph gland specification. Howev-
er, expression rebounds by the third larval instar (Fossett et al.,
2001). This complex expression pattern undoubtedly requires
regulatory controls not necessary during embryonic hemato-
poiesis. In particular, downregulation of ush may limit its
interaction with the GATA factors, Pannier (Pnr) and/or Srp,
which are required for lymph gland development (Mandal et
al., 2004). In our studies, forced pan-mesodermal expression
of ush and the resulting inhibition of lymph gland develop-
ment may have resulted from increased formation of Pnr:Ush
and/or SrpNC:Ush repressor complexes. It should be noted
that Pnr acts early to specify the cardiogenic mesoderm, which
gives rise to the lymph gland. However, continued expression
of Pnr within the developing lymph gland dramatically reduces
the number of cells that comprise this tissue. In contrast,
ectopic expression of Srp (presumably both SrpC and SrpNC)
increases the number of lymph gland cells (Mandal et al.,
2004). Thus, Ush may act early with Pnr or later with SrpNC
or during both embryonic time points to block lymph gland
production. Unfortunately, twiGal4-driven UAS-srp or UAS-
pnr embryos die before hatching, likely due to the disruption
of a number of mesodermal derivatives. This precludes an
assessment of their effect on lymph gland development in the
larvae. The production of lymph gland-specific drivers will
unable us to ascertain how dysregulation of Srp, Pnr, and Ush
affect lymph gland development across the embryonic and
larval stages.
Further support for wave-specific hematopoietic gene net-
works comes from observations suggesting that both Gcm and
Odd are expressed differentially during embryonic and lymph
gland hematopoiesis. Odd is expressed in the lymph gland but
not embryonic hemocytes (Ward and Skeath, 2000; Mandal et
al., 2004). In contrast, Gcm is expressed in the hemocyte
precursors and is required for plasmatocyte development
(Bernardoni et al., 1997). However, Gcm does not appear to
be expressed in the lymph gland (Bataille et al., 2005).
Moreover, these wave-specific hematopoietic factors may
influence ush expression. This is especially likely in the case
of Gcm, which is required for the production of the ush-
expressing plasmatocytes. Finally, the anterior lobe of the
mature lymph gland is highly compartmentalized, containing at
least three different zones. Ush is strongly expressed in the
cortical and medullary zones but is repressed in the posterior
signaling center (Jung et al., 2005). In contrast, the embryonic
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and the accompanying negative regulation of ush expression
(Lebestky et al., 2003; Jung et al., 2005). This initial
investigation of ush cis-regulation provides the necessary
resources to identify the diverse factors that control expression
across both hematopoietic waves.
Cell fate choice is controlled by genetic networks that
converge to regulate lineage-specific developmental programs.
The key components of these networks are transcriptional
regulators that form transient multiprotein complexes. These
complexes activate or repress gene expression by recognizing
specific cis-regulatory elements. This versatile interplay be-
tween transcription factor complexes and cis-elements consti-
tutes a gene-regulatory code for pluripotent progenitor
diversification. The studies presented here provide a framework
for the continued investigation of this process using a system
ideally suited for this purpose.
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